Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Post by scarlet1967on Dec 10, 2023 6:42pm
198 Views
Post# 35777100

Taimed raising money

Taimed raising money

 

"1.Date of the board of directors resolution:2023/12/07

2.Source of capital increase funds:

 Cash capital increase by the issuance of new shares

3.Whether to adopt shelf registration

  (Yes, please state issuance period/No):No

4.Total monetary value of the issuance and number of shares issued (shares

 issued not including those distributed to employees if consisting in

 capital increase from earnings or capital surplus):

 Total monetary value of issuance: The actual total amount raised depends on

 actual issue price per share.

 Total number of shares issued: 20,000,000 shares.

5.If adopting shelf registration, monetary value and number of shares

to be issued this time:NA

6.The remaining monetary value and shares after this issuance when

adopting shelf registration:NA

7.Par value per share:NTD$10

8.Issue price:

 Once the application is approved,the Chairman is authorized by

 the Board of Directors for pricing the new shares in accordance with the

 stipulations of ”Self-regulation Measures for Underwriters Providing

 Guidance to Companies in Raising and Issuing Negotiable Securities” and

 other relevant laws and regulations.

9.Number of shares subscribed for by or allocated to employees:

 In accordance with Article 267 of the Company Act, reserve 10% of new

 shares for subscription by the Company's employees to motivate employees.

10.Number of shares publicly sold:

 In accordance with Article 28-1 of Securities and Exchange Act, offer 10%

 of new shares put up for underwritten distribution by public subscription.

11.Ratio of shares subscribed by or allotted as stock

dividends to existing shareholders:

 80% of new shares are subscribed by original shareholders in

 proportion respectively to their original shareholding recorded on the

 register of shareholders on the record date of cash capital increase.

12.Handling method for fractional shares and shares

unsubscripted for by the deadline:

 Odd lots below one share subscribed by original shareholders shall be

 rounded up to whole shares by the shareholders themselves within

 five day from the suspension of share transfer to the company's stock

 transfer agent.

 Employees and original shareholders may waive subscription or round-up of

 odd lots below one share, and the Chairman is authorized to negotiate with

 specific individuals to fulfill the subscription at the issuance price.

13.Rights and obligations of these newly issued shares:

 Same as the previously issued common shares.

14.Utilization of the funds from the capital increase:

 Repayment of short-term bank loans and enrich working capital

15.Any other matters that need to be specified:

(1)It is proposed that the Chairman of the Board of Directors be authorized

   to determine the subscription record date, payment period, and capital

   increase record date after the Issuance becomes effective following the

   approval by the competent authority.

(2)It is proposed that the Chairman of the Board of Directors be authorized

   to determine the important matters of the Issuance, including the source

   of funding, allocation of proceeds, financing schedule and expected

   potential benefits, and, in case that there are any outstanding matters,

   any modification or amendment required by the competent authorities or

   due to change of circumstances.

(3)In this case of cash capital increase and issuance of ordinary shares,

   if the actual issuance price per share is adjusted due to market

   changes, resulting in insufficient funds raised, the difference will be

   covered by own funds, bank borrowings or other financing tools;

   however, if the funds raised increase, the excess will be used as the

   company’s working capital."

 

Taimed has mentioned multiple times they wanted to explore international cooperation for their first line maintenance therapy drugs "a $10 billion market" but it seems they they haven't been able to get any interest so far as they are now raising money in order to deal with short term loans and increasing operating capital. 

<< Previous
Bullboard Posts
Next >>